Ibio Inc (IBIO) Stock Price, Quote & News

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology

Sector: Healthcare

Phone: 979 446 0027

Website: ibioinc.com

Address:

11750 Sorrento Valley Road, Suite 200, San Diego, United States

Retail_Lives_Matter Jul. 14 at 9:29 PM

$IBIO straight up dog shiet I shoulda sold my burner acct shares for pennies Bagged again 🤣

0 · Reply

Rower5oh Jul. 10 at 4:56 PM

$IBIO This hasn’t gotten much attention, and I think it is huge. And we are now in the clinic with human subjects. Companies much earlier in the growth process have been purchased for quite a bit of cash https://ir.ibioinc.com/news-events/press-releases/detail/262/ibio-reports-single-dose-of-ibio-610-achieved-near-complete-active-activin-e-inhibition-through-eight-weeks-in-obese-nhp-study

1 · Reply

IBIO_KEVINTL Jul. 10 at 4:17 PM

$IBIO might be an MA coming tight lip And they want it cheap

0 · Reply

IBIO_KEVINTL Jul. 10 at 4:16 PM

$IBIO getting ready to buy this. Monday might be too late

0 · Reply

Retail_Lives_Matter Jul. 10 at 2:14 PM

$IBIO POFS

0 · Reply

Joelew22 Jul. 9 at 7:39 PM

$IBIO

2 · Reply

Retail_Lives_Matter Jul. 9 at 1:25 PM

$IBIO utter dog doo

1 · Reply

iBio_Principal_Skinner Jul. 8 at 4:49 AM

$IBIO when moon? When news? What’s Germany doing? Haven’t been here in a while, see a lot of the same names. And I’m still wayyyy down. But never going to sell, despite two reverse splits and a swift kick in the nuts. 🥜 See you next time!

0 · Reply

skitime Jul. 4 at 10:01 PM

$IBIO Well, just saying, no real change since July 2020 (after a 6 months pump)

1 · Reply

Mortimer2020 Jul. 2 at 11:58 PM

$IBIO

0 · Reply

iBio announces new preclinical data from IBIO-610 study

Jul 1, 2026, 7:00 AM EDT - 13 days ago

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

2026-06-08T10:37:48.000Z - 5 weeks ago

iBio initiated with an Outperform at Raymond James

Jun 4, 2026, 11:40 AM EDT - 5 weeks ago

iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 4:01 PM EDT - 6 weeks ago

iBio to Participate in Upcoming Healthcare Investor Conferences

2026-06-02T11:44:33.000Z - 6 weeks ago

iBio doses first participant in IBIO-600 trial

Jun 2, 2026, 7:00 AM EDT - 6 weeks ago

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

May 15, 2026, 7:00 AM EDT - 2 months ago

iBio, Inc. Slides: Corporate presentation

2026-05-12T21:36:01.000Z - 2 months ago

iBio reports Q3 EPS (7c), consensus (6c)

May 12, 2026, 4:05 PM EDT - 2 months ago

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 12, 2026, 4:00 PM EDT - 2 months ago

iBio, Inc. Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 2 months ago

iBio, Inc. Quarterly report: Q3 2026

Apr 8, 2026, 2:00 PM EDT - 3 months ago

iBio, Inc. Transcript: Status update

2026-04-08T11:12:57.000Z - 3 months ago

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

Apr 8, 2026, 7:00 AM EDT - 3 months ago

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

2026-03-30T16:21:02.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

ACOG

Mar 17, 2026, 4:00 PM EDT - 4 months ago

iBio, Inc. Transcript: Study update

2026-03-16T20:40:52.000Z - 4 months ago

iBio to provide update on cardiopulmonary program

Mar 16, 2026, 4:30 PM EDT - 4 months ago

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 9, 2026, 4:20 PM EDT - 4 months ago

iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:10:09.000Z - 4 months ago

iBio announces new preclinical data from study evaluating IBIO-610

Mar 9, 2026, 7:00 AM EDT - 4 months ago

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Mar 9, 2026, 7:00 AM EDT - 4 months ago

iBio, Inc. Slides: Corporate presentation

2026-03-02T21:34:02.000Z - 4 months ago

iBio initiated with a Buy at JonesResearch

2026-02-27T21:36:51.000Z - 4 months ago

iBio files $200M mixed securities shelf

2026-02-27T16:00:56.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Feb 27, 2026, 7:00 AM EST - 4 months ago

iBio, Inc. Registration statement: Registration Filing

Feb 26, 2026, 2:00 PM EST - 4 months ago

iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 7:00 AM EST - 5 months ago

iBio to Participate in Upcoming Investor Conferences

2026-02-10T21:13:10.000Z - 5 months ago

iBio reports Q2 EPS (9c), consensus (6c)

Feb 10, 2026, 4:05 PM EST - 5 months ago

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 10, 2026, 4:00 PM EST - 5 months ago

iBio, Inc. Quarterly report: Q2 2026

Feb 10, 2026, 4:00 PM EST - 5 months ago

iBio, Inc. Earnings release: Q2 2026

Jan 30, 2026, 7:00 AM EST - 5 months ago

iBio, Inc. Registration statement: Registration Filing

2026-01-09T12:13:56.000Z - 6 months ago

iBio prices 11.06M shares at $2.35 in private placement

Jan 9, 2026, 7:00 AM EST - 6 months ago

iBio Announces $26 Million Private Placement

2026-01-08T17:16:04.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today

2025-12-18T14:06:19.000Z - 7 months ago

iBio initiated with an Outperform at LifeSci Capital

ARWR WVE

2025-12-18T13:41:09.000Z - 7 months ago

iBio initiated with an Outperform at LifeSci Capital

2025-12-11T16:45:34.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

CAMP

2025-12-10T15:25:54.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

Dec 4, 2025, 8:45 AM EST - 7 months ago

iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 4:15 PM EST - 8 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 7:00 AM EST - 8 months ago

iBio, Inc. Slides: Corporate presentation

Nov 12, 2025, 4:01 PM EST - 8 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:00 PM EST - 8 months ago

iBio, Inc. Earnings release: Q1 2026

Nov 12, 2025, 4:00 PM EST - 8 months ago

iBio, Inc. Quarterly report: Q1 2026

Nov 10, 2025, 8:30 AM EST - 8 months ago

iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 30, 2025, 7:00 AM EDT - 9 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 23, 2025, 7:00 AM EDT - 9 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 21, 2025, 7:00 AM EDT - 9 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 6, 2025, 8:00 AM EDT - 10 months ago

iBio, Inc. Proxy statement: Proxy Filing

Sep 16, 2025, 7:00 AM EDT - 10 months ago

iBio, Inc. Slides: Corporate Presentation

Sep 5, 2025, 9:00 AM EDT - 11 months ago

iBio, Inc. Annual report: Q4 2025

Sep 5, 2025, 9:00 AM EDT - 11 months ago

iBio, Inc. Earnings release: Q4 2025

Sep 5, 2025, 7:30 AM EDT - 11 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Aug 25, 2025, 7:00 AM EDT - 11 months ago

iBio Announces Closing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 11 months ago

iBio Announces Pricing of $50 Million Public Offering

Aug 18, 2025, 4:01 PM EDT - 11 months ago

iBio Announces Proposed Public Offering

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Transcript: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Press release: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Slides: Study Update

Jun 24, 2025, 7:00 AM EDT - 1 year ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 23, 2025, 4:15 PM EDT - 1 year ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 16, 2025, 7:00 AM EDT - 1 year ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 13, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Registration statement: Registration Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Quarterly report: Q3 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Earnings release: Q3 2025

Apr 29, 2025, 1:43 PM EDT - 1 year ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 22, 2025, 8:00 AM EDT - 1 year ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 1 year ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q2 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q2 2025

Jan 31, 2025, 7:00 AM EST - 1 year ago

iBio, Inc. Registration statement: Registration Filing

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q1 2025

Oct 10, 2024, 8:00 AM EDT - 1 year ago

iBio, Inc. Proxy statement: Proxy Filing

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:00 PM EDT - 1 year ago

iBio, Inc. Earnings release: Q4 2024

Sep 20, 2024, 4:00 PM EDT - 1 year ago

iBio, Inc. Annual report: Q4 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jul 25, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Jun 3, 2024, 7:00 AM EDT - 2 years ago

iBio Closes Sale of Manufacturing Facility in Texas

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Quarterly report: Q3 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Earnings release: Q3 2024

May 13, 2024, 4:05 PM EDT - 2 years ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Apr 16, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Transcript: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Press release: Collaboration

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Quarterly report: Q2 2024

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Earnings release: Q2 2024

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 30, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

Nov 14, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Quarterly report: Q1 2024

Nov 14, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Earnings release: Q1 2024

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 27, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Oct 26, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing

Oct 16, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing

Oct 2, 2023, 6:45 AM EDT - 3 years ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 3 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:00 PM EDT - 3 years ago

iBio, Inc. Annual report: Q4 2023

Sep 21, 2023, 4:05 PM EDT - 3 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 3 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 7, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Registration statement: Registration Filing

Jun 27, 2023, 8:00 AM EDT - 3 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 3 years ago

iBio Forges Research Collaboration with the National Institutes of Health

Retail_Lives_Matter Jul. 14 at 9:29 PM

$IBIO straight up dog shiet I shoulda sold my burner acct shares for pennies Bagged again 🤣

0 · Reply

Rower5oh Jul. 10 at 4:56 PM

1 · Reply

IBIO_KEVINTL Jul. 10 at 4:17 PM

$IBIO might be an MA coming tight lip And they want it cheap

0 · Reply

IBIO_KEVINTL Jul. 10 at 4:16 PM

$IBIO getting ready to buy this. Monday might be too late

0 · Reply

Retail_Lives_Matter Jul. 10 at 2:14 PM

$IBIO POFS

0 · Reply

Joelew22 Jul. 9 at 7:39 PM

$IBIO

2 · Reply

Retail_Lives_Matter Jul. 9 at 1:25 PM

$IBIO utter dog doo

1 · Reply

iBio_Principal_Skinner Jul. 8 at 4:49 AM

0 · Reply

skitime Jul. 4 at 10:01 PM

$IBIO Well, just saying, no real change since July 2020 (after a 6 months pump)

1 · Reply

Mortimer2020 Jul. 2 at 11:58 PM

$IBIO

0 · Reply

Retail_Lives_Matter Jul. 2 at 4:58 PM

$IBIO what a POFS Do something Marty you bald fk

0 · Reply

Market_Paradise Jul. 1 at 5:27 PM

Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $GPUS $IBIO $ELTX $SOC 22

1 · Reply